Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Inclusion Criteria:

• Oocyte donors included in the oocyte donation program of Clinica EUGIN.
• 1st oocyte donation cycle at Clínica EUGIN.

Exclusion Criteria:

• Polycistic Ovarian syndrome (PCOs).
• Estradiol levels on day 2 of menstrual cycle >70 pg/ml.
• Hormone treatments up to 3 months before the oocyte donation cycle.
• Medical contraindication to the treatments used in the study